Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster
07 août 2023 16h45 HE
|
Zevra Therapeutics
CELEBRATION, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) ("Zevra" or “the Company"), a rare disease company melding science, data, and patient need to create...
Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023
02 août 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...
Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference
19 juil. 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced...
Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
20 juin 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., June 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, announced its...
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
13 juin 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced...
Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023
03 juin 2023 07h30 HE
|
Zevra Therapeutics
Zevra is a corporate sponsor of the Hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the...
Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results
15 mai 2023 16h05 HE
|
Zevra Therapeutics
Christal Mickle, Co-Founder and Chief Development Officer, appointed to serve as interim President and CEO effective June 1, 2023 Conference call and live audio webcast with slide presentation...
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023
10 mai 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today...
Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023
09 mai 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...
Zevra Announces Board of Directors and Leadership Changes
08 mai 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today...